1-<(2R,3S)-3-benzyloxycarbonylamino-2-hydroxy-4-phenylbutyryl>-N-tert-butyl-L-prolinamide | 191849-91-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: 1-<(2R,3S)-3-benzyloxycarbonylamino-2-hydroxy-4-phenylbutyryl>-N-tert-butyl-L-prolinamide
• 英文别名: (2R,3S)-3-(N-benzyloxycarbonyl)amino-2-hydroxy-4-phenylbutyryl-L-prolyl-tert-butyl amide；(2S,3R)-3-(N-benzyloxycarbonyl)amino-2-hydroxy-4-phenylbutyryl-L-prolyl-tert-butyl amide；benzyl N-[(1S,2R)-1-benzyl-3-[(2S)-2-(tert-butylcarbamoyl)pyrrolidin-1-yl]-2-hydroxy-3-oxo-propyl]carbamate；benzyl N-[(2S,3R)-4-[(2S)-2-(tert-butylcarbamoyl)pyrrolidin-1-yl]-3-hydroxy-4-oxo-1-phenylbutan-2-yl]carbamate
• CAS: 191849-91-9
• 化学式: C₂₇H₃₅N₃O₅
• 分子量: 481.592
• InChiKey: FEDKAIMWKYUZDG-RJGXRXQPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  35
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  108
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-<(2R,3S)-3-benzyloxycarbonylamino-2-hydroxy-4-phenylbutyryl>-N-tert-butyl-L-prolinamide 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 、 水 为溶剂， 反应 4.0h， 以93%的产率得到1-<(2R,3S)-3-amino-2-hydroxy-4-phenylbutyryl>-N-tert-butyl-L-prolinamide
  参考文献：
  名称：

  Synthesis and Human Immunodeficiency Virus(HIV)-1 protease Inhibitory Activity of Tripeptide Analogues Containing a Dioxoethylene Moiety.

  摘要：

  根据天然存在的人类免疫缺陷病毒（HIV）-1 蛋白酶抑制剂 RPI-856 A、B、C 和 D (1)的特征结构，设计了含有二氧乙烯分子的三肽类似物 2 和 3。所制备的化合物（2、3）在体外对 HIV-1 蛋白酶具有很高的抑制活性，与 RPI-856 A 相当。

  DOI：

  10.1248/cpb.42.2636
• 作为产物：
  描述：

  苄基(S)-1-(N-甲氧基-N-甲基氨基甲酰基)-2-苯乙基氨基甲酸酯 在 lithium hydroxide 、 sodium tetrahydroborate 、 叔丁基锂 、 1-羟基苯并三唑 、 臭氧 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 magnesium bromide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.83h， 生成 1-<(2R,3S)-3-benzyloxycarbonylamino-2-hydroxy-4-phenylbutyryl>-N-tert-butyl-L-prolinamide
  参考文献：
  名称：

  Selectivity in the Inhibition of HIV and FIV Protease: Inhibitory and Mechanistic Studies of Pyrrolidine-Containing .alpha.-Keto Amide and Hydroxyethylamine Core Structures

  摘要：

  This paper describes the development of new pyrrolidine-containing alpha-keto amide and hydroxyethylamine core structures as mechanism based inhibitors of the HIV and FIV proteases. It was found that the alpha-keto amide core structure 2 is approximately 300-fold better than the corresponding hydroxyethylamine isosteric structure and 1300-fold better than the corresponding phosphinic acid derivative as an inhibitor of the HIV protease. The alpha-keto amide is however not hydrated until it is bound to the HIV protease as indicated by the NMR study and the X-ray structural analysis. Further analysis of the inhibition activities of hydroxyethylamine isosteres containing modified pyrrolidine derivatives revealed that a cis-methoxy group at C-4 of the pyrrolidine would improve the binding 5-and 25-fold for the trans-isomer. When this strategy was applied to the alpha-keto amide isostere, a cis-benzyl ether at C-4 was found to enhance binding 3-fold. Of the core structures prepared as inhibitors of the HIV protease, none show significant inhibitory activity against the mechanistically identical FIV protease, and additional complementary groups are needed to improve inhibition.

  DOI：

  10.1021/ja00153a008

文献信息

• HIV protease inhibitors
  申请人：Wong Chi-Huey

  公开号：US06900238B1

  公开（公告）日：2005-05-31

  Combinatorial libraries of HIV and FIV protease inhibitors are characterized by α-keto amide or hydroxyethylamine core structures flanked by on one side by substituted pyrrolidines, piperidines, or azasugars and on the other side by phenylalanine, tyrosine, or substituted tyrosines. The libraries are synthesized via a one step coupling reaction. Highly efficacious drug candidates are identified by screening the libraries for binding and inhibitory activity against both HIV and FIV protease. Drug candidates displaying clinically useful activity against both HIV and FIV protease are identified as being potentially resistive against a loss of inhibitory activity due to development of resistant strains of HIV.

  HIV和FIV蛋白酶抑制剂的组合库以α-酮酰胺或羟乙基胺核心结构为特征，一侧为取代吡咯烷、哌啶或氮代糖，另一侧为苯丙氨酸、酪氨酸或取代酪氨酸。这些库是通过一步偶联反应合成的。通过筛选这些库，识别出对HIV和FIV蛋白酶的结合和抑制活性高效的药物候选化合物。对HIV和FIV蛋白酶都显示出临床有用活性的药物候选化合物被确定为潜在对抗由于HIV耐药株的发展而导致的抑制活性丧失。
• [EN] CYCLIC AMIDES OF 3-AMINO-2-HYDROXY-CARBOXYLIC ACIDS AS HIV-PROTEASE INHIBITORS
  申请人：SYNTEX (U.S.A.) INC.

  公开号：WO1993013066A1

  公开（公告）日：1993-07-08

  (EN) Compounds of formula (I) wherein R1 is alkoxycarbonyl, aralkoxycarbonyl, optionally substituted aralkanoyl, optionally substituted aroyl, optionally substituted heterocyclylcarbonyl, optionally substituted aryloxyalkanoyl, or optionally substituted heterocyclyloxyalkanoyl; R2 is hydrogen; R3 is alkyl optionally substituted by hydroxy, carbamoyl, monoalkylcarbamoyl, or dialkylcarbamoyl; R4 is optionally substituted aryl or optionally substituted aralkyl; R5 is hydrogen; R6 is hydroxy; or R5 and R6 together form oxo, and R7 is selected from the group consisting of (a), (b), (c), (d), (e), (f), (g), (h) and (i), wherein n is 0, 1 or 2; each R14 is independently hydroxy, alkyl, alkoxy, or phenyl; and R10 is alkoxycarbonyl or optionally substituted monoalkylcarbamoyl; as a single stereoisomer or as a mixture thereof; or as pharmaceutically acceptable salts thereof, are useful in treating disease-states which are alleviated by treatment with an HIV protease inhibitor.(FR) Des composés de la formule (I) dans laquelle R1 représente alcoxycarbonyle, aralcoxycarbonyle, aralcanoyle éventuellement substitué, aroyle éventuellement substitué, hétérocyclylcarbonyle éventuellement substitué, aryloxyalcanoyle éventuellement substitué, ou hétérocyclyloxyalcanoyle éventuellement substitué; R2 représente hydrogène; R3 représente alkyle éventuellement substitué par hydroxy, carbamoyle, monoalkylcarbamoyle ou dialkylcarbamoyle; R4 représente aryle éventuellement substitué ou aralkyle éventuellement substitué; R5 représente hydrogène; R6 représente hydroxy; ou R5 et R6 forment ensemble oxo; et R7 est sélectionné dans le groupe comprenant les formules (a), (b), (c), (d), (e), (f), (g), (h) et (i) dans lesquelles n vaut 0, 1 ou 2; chaque R14 représente indépendamment hydroxy, alkyle, alcoxy, ou phényle; et R10 représente alcoxycarbonyle ou monoalkylcarbamoyle éventuellement substitué; sous la forme d'un seul stéréoisomère ou d'un mélange de ceux-ci; ou bien sous la forme de sels pharmaceutiquement acceptables, sont utiles dans le traitement d'états pathologiques qui sont soulagés par traitement avec un inhibiteur de la protéase du VIH.
• Selectivity in the Inhibition of HIV and FIV Protease: Inhibitory and Mechanistic Studies of Pyrrolidine-Containing .alpha.-Keto Amide and Hydroxyethylamine Core Structures
  作者：Deborah H. Slee、Karen L. Laslo、John H. Elder、Ian R. Ollmann、Alla Gustchina、Jukka Kervinen、Alexander Zdanov、Alexander Wlodawer、Chi-Huey Wong

  DOI：10.1021/ja00153a008

  日期：1995.12

  This paper describes the development of new pyrrolidine-containing alpha-keto amide and hydroxyethylamine core structures as mechanism based inhibitors of the HIV and FIV proteases. It was found that the alpha-keto amide core structure 2 is approximately 300-fold better than the corresponding hydroxyethylamine isosteric structure and 1300-fold better than the corresponding phosphinic acid derivative as an inhibitor of the HIV protease. The alpha-keto amide is however not hydrated until it is bound to the HIV protease as indicated by the NMR study and the X-ray structural analysis. Further analysis of the inhibition activities of hydroxyethylamine isosteres containing modified pyrrolidine derivatives revealed that a cis-methoxy group at C-4 of the pyrrolidine would improve the binding 5-and 25-fold for the trans-isomer. When this strategy was applied to the alpha-keto amide isostere, a cis-benzyl ether at C-4 was found to enhance binding 3-fold. Of the core structures prepared as inhibitors of the HIV protease, none show significant inhibitory activity against the mechanistically identical FIV protease, and additional complementary groups are needed to improve inhibition.
• Synthesis and Human Immunodeficiency Virus(HIV)-1 protease Inhibitory Activity of Tripeptide Analogues Containing a Dioxoethylene Moiety.
  作者：Tomoyuki KITAZAKI、Tsuneo ASANO、Koichi KATO、Shoji KISHIMOTO、Katsumi ITOH

  DOI：10.1248/cpb.42.2636

  日期：——

  Tripeptide analogues 2 and 3 containing a dioxoethylene moiety were designed based on the characteristic structure of the naturally occurring human immunodeficiency virus (HIV)-1 protease inhibitors RPI-856 A, B, C and D (1). The compounds (2, 3) prepared showed high inhibitory activity, comparable to that of RPI-856 A, against HIV-1 protease in vitro.

  根据天然存在的人类免疫缺陷病毒（HIV）-1 蛋白酶抑制剂 RPI-856 A、B、C 和 D (1)的特征结构，设计了含有二氧乙烯分子的三肽类似物 2 和 3。所制备的化合物（2、3）在体外对 HIV-1 蛋白酶具有很高的抑制活性，与 RPI-856 A 相当。